Table 2 Secular trend of antimicrobial non-susceptibility in Acinetobacter baumannii complex from the 2002 to 2010 Taiwan Surveillance of Antimicrobial Resistance (TSAR) program
Antimicrobial agentsa | Resistance rate (%) by year | 2002 to 2006b | 2006 to 2010 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
2002 (298) | 2004 (259) | 2006 (304) | 2008 (418) | 2010 (361) | P | OR | 95% CI | P | OR | 95% CI | |
Amikacin | 63.1 | 68 | 70.7 | 66.5 | 64.3 | 0.046 | 1.19 | 1.003-1.411 | 0.081 | 0.865 | 0.735-1.018 |
Amp/Sulb | 57.4 | 64.1 | 57.6 | 61.5 | 59.6 | 0.971 | 1.003 | 0.852-1.180 | 0.637 | 1.038 | 0.889-1.212 |
Cefepime | 64.1 | 70.7 | 74 | 71.3 | 60.9 | 0.008 | 1.265 | 1.062-1.507 | <0.001 | 0.731 | 0.619-0.864 |
Ceftazidime | 68.1 | 73.4 | 76.6 | 74.6 | 70.4 | 0.019 | 1.241 | 1.036-1.486 | 0.063 | 0.848 | 0.712-1.009 |
Ciprofloxacin | 68.8 | 75.3 | 76 | 75.4 | 75.3 | 0.047 | 1.202 | 1.002-1.441 | 0.853 | 0.983 | 0.824-1.174 |
Gentamicin | 73.5 | 78.8 | 76.6 | 70.3 | 72.9 | 0.367 | 1.09 | 0.904-1.315 | 0.311 | 0.915 | 0.770-1.087 |
Imipenem | 3.4 | 18.1 | 31.6 | 51.4 | 58.7 | <0.001 | 3.043 | 2.348-3.944 | <0.001 | 1.732 | 1.478-2.029 |
Levofloxacin | 66.1 | 72.6 | 74.3 | 73.9 | 71.2 | 0.027 | 1.222 | 1.023-1.458 | 0.349 | 0.921 | 0.775-1.094 |
Pip/Tazo | 62.8 | 76.8 | 75.3 | 74.6 | 68.4 | 0.001 | 1.363 | 1.139-1.631 | 0.041 | 0.835 | 0.703-0.992 |
TMP/SMX | 73.8 | 75.7 | NTc | NT | 71.5 | NDd | ND | ||||